Paul Kang

Paul Kang has been involved in the development and application of antibody generation technologies for over 20 years at ImmGenics Pharmaceuticals, Abgenix Inc, and Amgen Inc. Paul played an instrumental role in the development and deployment of novel first in class antibody discovery technologies including ImmGenics’ SLAM technology (Selected Lymphocyte Antibody Method) and Abgenix Inc.’s XenoMouse Technology which was subsequently acquired by Amgen, At Amgen, Paul oversaw Amgen British Columbia’s Preclinical In Vitro Cellular Assay and In Vivo Pharmacology research teams, whose primary responsibilities were the screening and characterization of XenoMouse derived antibodies. Paul subsequently, left Amgen and was a co-founder of Innovative Targeting Solutions. As CSO of ITS, Paul oversaw the advancement of the company’s HuTARG protein engineering platform and the company’s six pharma collaborations. Paul is also a co-founder of A2 Biotherapeutics and Tentarix Biotherapeutics.

Paul holds a Bachelor of Science from Simon Fraser University.